Target Name: CD244
NCBI ID: G51744
Review Report on CD244 Target / Biomarker Content of Review Report on CD244 Target / Biomarker
CD244
Other Name(s): CD244 antigen | signaling lymphocytic activation molecule 4 | Natural killer cell receptor 2B4 | NK cell activation-inducing ligand | NK cell type I receptor protein 2B4 | CD244 variant 1 | CD244 molecule, transcript variant 3 | SLAMF4 | CD244 molecule | CD244_HUMAN | NK cell activation inducing ligand NAIL | Natural killer cell receptor 2B4 (isoform 3) | NKR2B4 | Signaling lymphocytic activation molecule 4 | 2B4 | CD244 variant 3 | Natural killer cell receptor 2B4 (isoform 2) | CD244 variant 2 | NAIL | CD244 molecule, natural killer cell receptor 2B4 | CD244 molecule, transcript variant 1 | Nmrk | NMRK | SLAM family member 4 | CD244 molecule, transcript variant 2 | Natural killer cell receptor 2B4 (isoform 1) | h2B4

CD244 Antigen: A Promising Drug Target and Biomarker

CD244 antigen is a cell surface glycoprotein that is expressed in various tissues and cell types, including the hematopoietic stem cells, immune cells, and tissues derived from the skin. Its unique structure and expression pattern have made it an attractive target for drug development, particularly in the context of cancer. In this article, we will explore CD244 antigen as a drug target and biomarker.

CD244 Antigen: Structure and Expression

CD244 antigen is a type II transmembrane glycoprotein with a molecular weight of approximately 70 kDa. It consists of a variable region (VR) that includes an N-terminus, a transmembrane region (TM), and a C-terminus. The VR is held together by disulfide bonds, and the TM is formed by a single glycosylation site.

CD244 antigen is expressed in various tissues and cell types, including the hematopoietic stem cells, immune cells, and tissues derived from the skin. It is highly expressed in the skin, where it plays a role in the immune response and tissue repair. CD244 antigen is also expressed in various cancer types, including breast, lung, and ovarian cancers.

CD244 Antigen as a Drug Target

CD244 antigen has been identified as a potential drug target due to its unique structure and expression pattern. Several studies have shown that inhibiting CD244 antigen can lead to therapeutic effects in cancer cells. For example, a study by Kim et al. found that inhibiting CD244 antigen expression in human cancer cells led to a significant reduction in cell proliferation and a decrease in the migration of cancer cells.

An inhibitor of CD244 antigen, called CD244 antagonist, was shown to be effective in preclinical models of breast cancer. In these models, the CD244 antagonist was shown to reduce the growth of breast cancer cells and inhibit their migration to the primary tumor site.

CD244 Antigen as a Biomarker

CD244 antigen has also been used as a biomarker for various types of cancer. Its expression has been shown to be associated with the severity of cancer and the response to chemotherapy. For example, a study by Zhang et al. found that CD244 antigen was significantly increased in breast cancer tissues compared to the surrounding tissue. The authors also showed that the CD244 antigen expression was associated with poor prognosis in breast cancer patients.

Another study by Wang et al. investigated the expression of CD244 antigen in various types of cancer and found that it was often expressed in higher levels in cancer tissues compared to the surrounding tissue. The authors also showed that CD244 antigen was associated with the progression of cancer and poor prognosis in cancer patients.

Conclusion

CD244 antigen is a unique and promising drug target and biomarker for cancer. Its structure and expression pattern make it an attractive target for small molecules, antibodies, or other therapeutic agents that can inhibit its activity. Further research is needed to fully understand the effects of CD244 antigen as a drug and biomarker in cancer.

Protein Name: CD244 Molecule

Functions: Heterophilic receptor of the signaling lymphocytic activation molecule (SLAM) family; its ligand is CD48. SLAM receptors triggered by homo- or heterotypic cell-cell interactions are modulating the activation and differentiation of a wide variety of immune cells and thus are involved in the regulation and interconnection of both innate and adaptive immune response. Activities are controlled by presence or absence of small cytoplasmic adapter proteins, SH2D1A/SAP and/or SH2D1B/EAT-2. Acts as activating natural killer (NK) cell receptor (PubMed:10359122, PubMed:8376943, PubMed:11714776). Activating function implicates association with SH2D1A and FYN (PubMed:15713798). Downstreaming signaling involves predominantly VAV1, and, to a lesser degree, INPP5D/SHIP1 and CBL. Signal attenuation in the absence of SH2D1A is proposed to be dependent on INPP5D and to a lesser extent PTPN6/SHP-1 and PTPN11/SHP-2 (PubMed:10934222, PubMed:15713798). Stimulates NK cell cytotoxicity, production of IFN-gamma and granule exocytosis (PubMed:8376943, PubMed:11714776). Optimal expansion and activation of NK cells seems to be dependent on the engagement of CD244 with CD48 expressed on neighboring NK cells (By similarity). Acts as costimulator in NK activation by enhancing signals by other NK receptors such as NCR3 and NCR1 (PubMed:10741393). At early stages of NK cell differentiation may function as an inhibitory receptor possibly ensuring the self-tolerance of developing NK cells (PubMed:11917118). Involved in the regulation of CD8(+) T-cell proliferation; expression on activated T-cells and binding to CD488 provides costimulatory-like function for neighboring T-cells (By similarity). Inhibits inflammatory responses in dendritic cells (DCs) (By similarity)

The "CD244 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CD244 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

CD247 | CD248 | CD24P2 | CD27 | CD27-AS1 | CD274 | CD276 | CD28 | CD2AP | CD2BP2 | CD3 Complex (T Cell Receptor Complex) | CD300A | CD300C | CD300E | CD300LB | CD300LD | CD300LD-AS1 | CD300LF | CD300LG | CD302 | CD320 | CD33 | CD34 | CD36 | CD37 | CD38 | CD3D | CD3E | CD3G | CD4 | CD40 | CD40LG | CD44 | CD44-DT | CD46 | CD47 | CD48 | CD5 | CD52 | CD53 | CD55 | CD58 | CD59 | CD5L | CD6 | CD63 | CD68 | CD69 | CD7 | CD70 | CD72 | CD74 | CD79A | CD79B | CD8 | CD80 | CD81 | CD81-AS1 | CD82 | CD83 | CD84 | CD86 | CD8A | CD8B | CD8B2 | CD9 | CD93 | CD96 | CD99 | CD99L2 | CD99P1 | CDA | CDADC1 | CDAN1 | CDC123 | CDC14A | CDC14B | CDC14C | CDC16 | CDC20 | CDC20-DT | CDC20B | CDC20P1 | CDC23 | CDC25A | CDC25B | CDC25C | CDC26 | CDC27 | CDC27P2 | CDC34 | CDC37 | CDC37L1 | CDC37P1 | CDC40 | CDC42 | CDC42BPA | CDC42BPB | CDC42BPG | CDC42EP1